Alpha Tau Medical Ltd (DRTS) Price & Analysis

Compare

122 Followers

DRTS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.11 - $4.69

Previous CloseN/A

Volume116.73K

Average Volume (3M)66.09K

Market Cap

$370.14M

Enterprise Value$180.76M

Total Cash (Recent Filing)$79.70M

Total Debt (Recent Filing)$13.31M

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Nov 25, 2025

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding84,699,720

10 Day Avg. Volume68,574

30 Day Avg. Volume66,090

Financial Highlights & Ratios

PEG Ratio-0.96

Price to Book (P/B)3.46

Price to Sales (P/S)0.00

P/FCF Ratio-9.84

Enterprise Value/Market Cap0.49

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-5.62

Forecast

1Y Price Target

$8.50

Price Target Upside93.18% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAlpha Tau Medical announced that the first patient has been treated in the U.S. pilot study of Alpha DaRT in patients with pancreatic cancer.

Regulatory ProgressThe response to the request for pre-market approval for the treatment of recurrent head & neck cancer is expected, which will further de-risk the Alpha DaRT platform.

Bears Say

Financial PerformanceNet loss was $10.1M, or ($0.13) per share, moderately higher than the estimated loss of $9.3M.

Alpha Tau Medical Ltd News

Alpha Tau Medical’s Innovative Approach in Pancreatic Cancer Treatment: A Study Update

Alpha Tau Medical Ltd (($DRTS)) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd (DRTS)...

26d ago

DRTS

Alpha Tau Medical’s Pivotal Study on DaRT Treatment for Skin Cancer: A Market Perspective

Alpha Tau Medical Ltd (($DRTS)) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd (DRTS)...

29d ago

DRTS

Alpha Tau Medical’s DaRT224 Study: A Potential Game-Changer in Cancer Treatment

Alpha Tau Medical Ltd (($DRTS)) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd. is...

29d ago

DRTS

Alpha Tau Treats First Patient in U.S. Pancreatic Cancer Trial

An announcement from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On September 2, 2025, Alpha...

1M ago

DRTS

Alpha Tau treats first patient in U.S. multi-center pancreatic cancer trial

Alpha Tau (DRTS) Medical announced that the first patient has been treated in its U.S. multi-center pancreatic cancer...

1M ago

DRTS

Alpha Tau Medical to Engage Investors at September Conferences

Alpha Tau Medical Ltd ( ($DRTS) ) just unveiled an update. On August 27, 2025, Alpha Tau Medical...

1M ago

DRTS

Alpha Tau Medical’s Innovative Approach to Pancreatic Cancer Treatment: A Study Update

Alpha Tau Medical Ltd (($DRTS)) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd is...

2M ago

DRTS

Promising Developments and Strong Financials Support Buy Rating for Alpha Tau Medical Ltd.

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Alpha Tau Medical Ltd and keeping the...

2M ago

DRTS

Alpha Tau Medical Ltd: Strategic Advancements and Promising Growth Potential with Alpha DaRT Technology

In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Alpha Tau Medical Ltd,...

2M ago

DRTS

Alpha Tau reports 1H EPS (25c) vs. (22c) last year

“The Company’s focus activities continue to coalesce, with an increasing emphasis on U.S. clinical trials, priority indications in...

2M ago

DRTS

Alpha Tau Medical Ltd. Reports Strong Financial Growth in H1 2025

Alpha Tau Medical Ltd ( ($DRTS) ) has provided an update. On August 11, 2025, Alpha Tau Medical...

2M ago

DRTS

Alpha Tau Medical’s Innovative Pancreatic Cancer Study: A Potential Game-Changer?

Alpha Tau Medical Ltd (($DRTS)) announced an update on their ongoing clinical study. Alpha Tau Medical Ltd is...

3M ago

DRTS

Alpha Tau files to sell 3.46M shares of common stock for holders

16:57 EDT Alpha Tau (DRTS) files to sell 3.46M shares of common stock for holders Published first on...

3M ago

DRTS

Closing Bell Movers: Trip.com slips 3% after results despite topping estimates

In the opening 30 minutes of the evening session, U.S. equity futures are mixed, with S&P 500 down...

5M ago

RHP

AGYS

DRTS FAQ

What was Alpha Tau Medical Ltd’s price range in the past 12 months?

Alpha Tau Medical Ltd lowest stock price was $2.11 and its highest was $4.69 in the past 12 months.

What is Alpha Tau Medical Ltd’s market cap?

Alpha Tau Medical Ltd’s market cap is $370.14M.

When is Alpha Tau Medical Ltd’s upcoming earnings report date?

Alpha Tau Medical Ltd’s upcoming earnings report date is Nov 25, 2025 which is in 52 days.

How were Alpha Tau Medical Ltd’s earnings last quarter?

Alpha Tau Medical Ltd released its earnings results on Aug 11, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.019.

Is Alpha Tau Medical Ltd overvalued?

According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alpha Tau Medical Ltd pay dividends?

Alpha Tau Medical Ltd does not currently pay dividends.

What is Alpha Tau Medical Ltd’s EPS estimate?

Alpha Tau Medical Ltd’s EPS estimate is -0.12.

How many shares outstanding does Alpha Tau Medical Ltd have?

Alpha Tau Medical Ltd has 84,699,720 shares outstanding.

What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?

Alpha Tau Medical Ltd reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went down -8.708%.

Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?

Currently, no hedge funds are holding shares in DRTS

Alpha Tau Medical Ltd Stock Smart Score

Neutral

Fundamentals

Return on Equity

-43.83%

Trailing 12-Months

Asset Growth

15.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alpha Tau Medical Ltd

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd (DRTS) Earnings & Revenues

Historic Earnings Reports

DRTS Stock 12 Month Forecast

Average Price Target

$8.50

▲(93.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","10":"$10","3.25":"$3.25","5.5":"$5.5","7.75":"$7.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.25,5.5,7.75,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.48,3.9046153846153846,4.329230769230769,4.753846153846154,5.178461538461538,5.603076923076923,6.027692307692307,6.452307692307691,6.8769230769230765,7.3015384615384615,7.726153846153846,8.15076923076923,8.575384615384614,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.48,3.8661538461538463,4.252307692307692,4.638461538461538,5.024615384615385,5.4107692307692306,5.796923076923077,6.183076923076923,6.569230769230769,6.955384615384615,7.341538461538461,7.7276923076923065,8.113846153846154,{"y":8.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.48,3.8276923076923075,4.1753846153846155,4.523076923076923,4.8707692307692305,5.218461538461538,5.566153846153846,5.913846153846153,6.261538461538461,6.609230769230768,6.956923076923076,7.304615384615384,7.6523076923076925,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >